Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod maintenance therapy in moderately to severely active Crohn's disease
NL-OMON54627Phase 3Active, not recruiting
- Sponsor
- Shanghai Celgen Biopharma
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Ozanimod with Placebo (2 arms). Primary endpoints: Clinical remission at Week 52 and Endoscopic response at Week 52. Started Jan 2021; status: active, not recruiting.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON54627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54627.